Phase 3 study of sirolimus for posterior segment uveitis achieves primary endpoint Healio Santen Inc. announced that its first of two global phase 3 studies analyzing the efficacy and safety of intravitreal injections of sirolimus in noninfectious posterior segment uveitis patients has met its primary endpoint. The Study Assessing Double ... |
